2005年诺贝尔生理或医学奖得主，西澳大学临床微生物学教授，与罗宾·沃伦发现了幽门螺杆菌以及这种细菌在胃炎和胃溃疡等疾病中的作用。马歇尔教授对华友好，积极推动中澳生物医学领域的合作，2011年当选中国工程院外籍院士，2014年获得中国政府“友谊奖”。
侯志波博士毕业于香港科技大学生物化学系，拥有PCT国际发明专利1项，5项中国发明专利，长期从事生物技术和临床诊断等领域的基础理论和应用研究，推广纳米胶乳免疫比浊技术，并在Nature Medicine等国际著名杂志发表10余篇高水平SCI论文，领导团队承担了多项香港和国家级科技攻关项目。2013年入选“深圳市海外高层次人才”，在企业融资和产业链建设方面成就卓著，成功联合上市公司漳州片仔癀药业股份有限公司，产业化临床诊断试剂67项，已经全部获得医疗器械注册证（体外诊断试剂）。
郑敬元博士于2010年在新南威尔斯大学（悉尼）完成博士学位。之后在西澳大学马歇尔传染病与培训中心担任研究助理和幽门螺杆菌实验室负责人。郑博士对幽门螺杆菌的耐药以及其全基因组结构有着浓厚的兴趣，跟随诺贝尔奖得主巴里马歇尔教授一直在关注着幽门螺杆菌的耐药情况，凭借成熟的基因测序技术分析幽门螺杆菌的基因突变与耐药的关系，并希望在幽门螺杆菌的基因中寻找到致病的因素。同时，郑博士也通过互联网www.helicobacter.com 以及 www.helico.com向世界各地的病患提供最新资讯，希望患者能早日脱离幽门螺杆菌的折磨。
Dr. Willinge is a former senior executive of IBM Corporation. Dr. Willinge currently serves as a Director and Chairman on a number of unlisted and listed public and private company boards internationally. He has lived and worked in Hong Kong for 15 years.
He is a Fellow of the Australian Institute of Company Directors (AICD) and a Fellow of the Hong Kong Institute of Directors. He is chair of AICD Hong Kong Committee. He graduated with a Bachelor of Science Degree from the University of Melbourne. He gained a Graduate Diploma of Company Directors from the University of New England in 1992 and was awarded a Graduate Diploma of Applied Finance and Investment from the Securities of Institute of Australia in 1995. He also completed the INSEAD Asian International Executive Programme in 2004 and attended a number of Harvard sponsored IBM management programs over many years.
He is an Adjunct Professor of Business Studies at Curtin University in Australia and previously served a full term of nine years on the Advisory Board of Curtin Business School. In February 2014, he received an honorary degree of Doctor of Technology from Curtin University.